{
  "docId": "019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "docSlug": "5bc6ecf6756c39ce2bfe560c6ffb0fc7",
  "documentTitle": "ATAI | Investor Presentation Deck | 31 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 31,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide demonstrates an inverted U-shaped dose response curve.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e8f5-748b-98ae-3f4a3c3c68f5/9",
  "deckHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "deckJsonHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5.json",
  "deckAnchorHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.35,
        "x": 0.63,
        "y": 0.016
      },
      "kind": "chart",
      "text": "Delayed recall and Verbal learning Cohen's d effect size charts",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "410b4a57-58b8-4580-ac89-7624d4f9efcd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.55,
        "x": 0.04,
        "y": 0.055
      },
      "kind": "list",
      "text": "1. RL-007 showed statistically significant pro-cognitive effects on learning and memory within the \"Intermediate-Dose escalation\" 40mg to 80mg arm. 2. The 40 to 80mg arm patients also reported a statistically significant improvement on the Cognitive and Physical Function Questionnaire (p = 0.021). 3. Inverted U-shaped dose response whereby intermediate doses yield greater clinical activity is replicated and consistent with from prior clinical and preclinical studies",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbeee47d-e489-4e8e-94f3-8a066e40da6e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.55,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Phase II, randomized, placebo-controlled, crossover clinical study in subjects with diabetic peripheral neuropathic pain (DPNP) that assessed improvements in verbal learning and memory as an exploratory endpoint. 4-week placebo periods were compared to 4-week RL-007 periods.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "384581fb-d1d1-4eb5-9546-b487174278e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.03,
        "y": 0.1
      },
      "kind": "paragraph",
      "text": "Third-Party Phase 2 study in DPNP showed statistically significant positive cognitive signals (exploratory endpoints)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4577b2b1-2a12-4196-8632-0721034108c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Note: * = P< 0.05 vs Placebo; N=60 patients/treatment group; dosed TID = 3x/day dosing; randomized, cross-over design",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e07f1227-5b6c-4df6-bab1-7575a9da37d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Clinical Evidence: Efficacy on Cognitive Endpoints in a Phase 2 Study",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "533d1d36-5de6-4d7b-9952-b0e27b9f1643",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 6,
      "beatId": "3567efa9-5c4b-4d3c-88d1-7a53a3a212bc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The presentation showcases the progress and achievements of atai Life Sciences' drug development programs, including efficacy and safety data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 6,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "70da09d2-e8b7-478f-a3d9-ef5654b6b7c9",
      "evidence": "The presentation presents data and results from clinical trials, demonstrating the potential for atai Life Sciences' treatments to become first and best-in-class.",
      "position": 1,
      "objective": "Showcase the potential for first and best-in-class treatments",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}